JenaValve Technology announced that the U.S. Federal Trade Commission moved to block the company’s proposed acquisition by Edwards Lifesciences (EW). “JenaValve respectfully disagrees with the FTC’s decision and remains committed to completing the acquisition. JenaValve remains confident in both its rationale for the transaction and the value it will bring to the hundreds of thousands of patients suffering from aortic regurgitation. JenaValve intends to join Edwards to defend this case in court to complete the acquisition,” the company stated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- FTC Blocks Edwards Lifesciences’ Acquisition of JenaValve
- Edwards Lifesciences raises FY25 adjusted EPS view to high-end of $2.45-$2.55
- Edwards to pursue regulatory approval after FTC action to block JenaValve deal
- Edwards Lifesciences’ SAPIEN 3 Valve Study: A Real-World Evaluation
- Edwards Lifesciences’ PASCAL System: A Promising Update in Tricuspid Valve Repair